Brief: Eiger, AnGes Receive Approval for Zokinvy (lonafarnib) for Hutchinson- Gilford Progeria Syndrome and Processing-Deficient Progeroid Laminopathies in Japan
18/01/2024 23:09
Jan 18 (Reuters) - Eiger BioPharmaceuticals Inc
EIGR.O :
* EIGER AND PARTNER, ANGES, RECEIVE APPROVAL FOR ZOKINVY®
(LONAFARNIB) FOR HUTCHINSON- GILFORD PROGERIA SYNDROME AND
PROCESSING-DEFICIENT PROGEROID LAMINOPATHIES IN JAPAN
* EIGER BIOPHARMACEUTICALS INC - TO RECEIVE $500,000
APPROVAL
MILESTONE PAYMENT FROM ANGES
Source text for Eikon: ID:nPn2mWdw6a
Further company coverage: EIGR.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Eiger Biopharmaceuticals
See all newsBrief: Eiger Biopharmaceuticals On Sept 5, Bankruptcy Court Entered Order Confirming Fifth Amended Joint Plan Of Liquidation Of Co & Its Debtor Affiliates
Amylyx to buy bankrupt Eiger's experimental drug to treat low blood sugar
Brief: Eiger Biopharmaceuticals And Amylyx Entered Into An Asset Purchase Agreement
Eiger BioPharmaceuticals Inc reports results for the quarter ended in December - Earnings Summary
Eiger BioPharmaceuticals Inc expected to post a loss of $7.50 a share - Earnings Preview